Valuation: Vaxart, Inc.

Market Cap 109M 95.31M 88.75M 81.63M 153M 10.38B 156M 1.05B 412M 5.15B 408M 399M 17.78B P/E 2026 *
-2.31x
P/E 2027 * -0.45x
Enterprise Value 109M 95.31M 88.75M 81.63M 153M 10.38B 156M 1.05B 412M 5.15B 408M 399M 17.78B EV / Sales 2026 *
0.54x
EV / Sales 2027 * 46.2x
Free-Float
98.3%
Yield 2026 *
-
Yield 2027 * -
1 day+7.09%
1 week-3.60%
Current month-20.33%
1 month-10.66%
3 months-38.10%
6 months-25.58%
Current year+39.15%
1 week 0.44
Extreme 0.44
0.62
1 month 0.44
Extreme 0.44
0.65
Current year 0.34
Extreme 0.3434
0.84
1 year 0.3
Extreme 0.305
0.84
3 years 0.26
Extreme 0.2606
1.54
5 years 0.26
Extreme 0.2606
10.33
10 years 0.25
Extreme 0.2543
24.9
Manager TitleAgeSince
Chief Executive Officer 60 18/03/2024
Chief Tech/Sci/R&D Officer 59 01/03/2024
Director of Finance/CFO - 19/05/2025
Director TitleAgeSince
Director/Board Member 68 21/04/2021
Director/Board Member 76 04/08/2022
Director/Board Member 79 01/01/2022
Date Insider Type Main position Quantity % Market Cap.
16/07/26 Free

Director

24,925 0.0103%
16/07/26 Free

Director

118,100 0.0488%
16/07/26 Free

Director

118,100 0.0488%
Change 5-day change 1-year change 3-year change Capi.($)
+0.63%-3.60%+20.50%-35.73% 109M
-2.25%+2.44%+53.17%+64.57% 56.19B
-1.32%-0.97%+38.41%+77.52% 54.83B
+1.49%+0.31%-19.82%-11.95% 23.04B
-0.57%-2.70%+0.17%+410.44% 22.7B
-0.21%+0.84%+22.48%-7.92% 20.23B
0.00%+3.30%+28.01%-29.07% 17.83B
-0.97%+0.89%+37.28%+539.62% 15.65B
-6.69%-5.11%+166.00%+304.89% 15.24B
+1.25%+1.76%+23.93%+188.32% 14.03B
Average -0.22%+0.06%+37.01%+150.07% 23.98B
Weighted average by Cap. -1.17%+0.42%+37.72%+133.30%

Financials

2026 *2027 *
Net sales 200M 176M 164M 151M 282M 19.15B 287M 1.94B 761M 9.5B 753M 736M 32.81B 2.35M 2.06M 1.92M 1.77M 3.31M 225M 3.37M 22.78M 8.92M 111M 8.82M 8.63M 385M
Net income -24.4M -21.42M -19.94M -18.34M -34.39M -2.33B -34.98M -237M -92.61M -1.16B -91.62M -89.64M -4B -266M -234M -218M -200M -375M -25.43B -381M -2.58B -1.01B -12.61B -999M -978M -43.57B
Net Debt - -
Logo Vaxart, Inc.
Vaxart, Inc. is a clinical-stage biotechnology company that is primarily focused on the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology (VAAST) proprietary oral vaccine platform. Its vaccines are designed to be administered using pills that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. The Company’s development programs include pill vaccines designed to protect against coronavirus, norovirus and influenza, as well as a therapeutic vaccine for human papillomavirus (HPV), its first immune-oncology indication. The Company's platform technology employs a vector-based approach and consists of various components, such as vector, antigen, and adjuvant. A vector is a virus used as a carrier to deliver DNA coding for vaccine antigens and an adjuvant selected to activate the immune system. An antigen is a viral or bacterial protein that stimulates an immune response to the targeted pathogen.
Employees
65
Date Price Change Volume
28/07/26 $0.4820 +7.09% 294,889
27/07/26 $0.4501 -9.07% 443,285
24/07/26 $0.4950 -0.90% 193,957
23/07/26 $0.4995 +4.50% 503,141
22/07/26 $0.4780 -5.02% 346,063
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
0.4501USD
Average target price
3.333USD
Spread / Average Target
+640.58%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. VXRT Stock